Physician profile
Samir Kumar Nath
NPI 1386660876
$1,703.00
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.64 · 2020: $125 · 2021: $236 · 2022: $259 · 2023: $228 · 2024: $451 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $28.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.39 |
| Education | $28.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.61 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.78 | 2019-2025 | Trulance, Plenvu |
| Janssen Biotech, INC. | $138.58 | 2022-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $131.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.55 | 2023-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $115.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $96.59 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $79.11 | 2023-2024 | Dificid |
| Celgene Corporation | $56.18 | 2024 | Zeposia |
| Lilly USA, LLC | $53.63 | 2024-2025 | Omvoh |
| Medtronic, INC. | $46.13 | 2021-2023 | Gi Genius |
| Braintree Laboratories, INC. | $39.90 | 2020-2023 | Suflave |
| Redhill Biopharma INC. | $37.59 | 2021 | |
| Genzyme Corporation | $26.49 | 2022 | |
| Ironwood Pharmaceuticals, INC | $22.41 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.36 | 2024 | |
| Intercept Pharmaceuticals, INC. | $15.30 | 2022 | |
| Novo Nordisk INC | $14.54 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $14.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.